Real-world evidence (RWE) has become central to evaluating therapies, medical products, and health interventions—providing insight into how they perform outside controlled clinical trials. As healthcare systems seek more timely, representative, and cost-effective approaches to evidence generation, real-world data (RWD) is increasingly used to inform regulatory decisions, guide clinical practice, and shape health policy.
As RWE gains traction, fundamental questions remain: How do we ensure
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Caris Life Sciences Announces Pricing of Initial Public Offering
What You Should Know:
- Caris Life Sciences® (Caris), an AI TechBio company and pioneer in precision medicine, today announced the pricing of its initial public offering (IPO) of 23,529,412 shares of its common stock at a public offering price of $21.00 per share.
- The shares are expected to begin trading on the Nasdaq Global Select Market on June 18, 2025, under the ticker symbol “CAI.” The offering is expected to close on June 20, 2025, subject to customary closing
Read More
Omada Health Data Shows Companion Program Significantly Boosts GLP-1 Medication Persistence
What You Should Know:
- Omada Health, the virtual between-visit healthcare provider released new data demonstrating that its GLP-1 companion program significantly improves persistence rates for GLP-1 medications.
- The analysis found that members in Omada's program achieved weight loss results similar to those seen in controlled research settings, underscoring the importance of comprehensive support for individuals on these transformative medications.
- The findings provide
Read More
Quilt Health Raises $6M to Modernize Clinical Trial Access for Complex Diseases
What You Should Know:
- Quilt Health, a digital health company dedicated to bridging gaps in treatment access for complex diseases secures $6M in seed funding round, bringing its total funding to $8M. The round was led by MaC Venture Capital and Underscore Ventures, with participation from Meridian Street Capital, BoxGroup, Watershed VC, and Coalition Operators.
- Founded with an initial focus on sickle cell disease, the company plans to use the new capital to rapidly expand into
Read More
Eliminating Cancer Treatment Side-Effects Through Targeted Drug Delivery
Last year, the American Cancer Society predicted that in 2024, the US would reach two million annual new cancer cases for the first time in history. This number is staggering and signifies that cancer is truly a disease that impacts many lives each day.
While not all of these cases result in the grueling treatment associated with chemotherapy and radiation, many of those diagnosed will face the difficult road to recovery. Patients in chemotherapy experience a range of symptoms, from
Read More
Novo Nordisk Amps Up Drug Discovery with Gefion AI Supercomputer
What You Should Know:
-DCAI today announced that Novo Nordisk has become a customer of the Gefion AI supercomputer.
- Through this agreement, Novo Nordisk will gain access to Gefion's unparalleled computational capabilities to process vast datasets, with a goal of transforming drug discovery and development as well as driving healthcare innovation.
AI-Powered Supercomputing Alliance to Advance Drug Discovery at Scale
In a landmark multiyear agreement, Novo Nordisk and Gefion have
Read More
Lieber Institute and AWS Collaborate to Optimize Drug Discovery for Brain Disorders
What You Should Know:
- The Lieber Institute for Brain Development (LIBD) is expanding its technology capabilities on Amazon Web Services (AWS), migrating its IT infrastructure to fully utilize AWS generative AI and compute services to advance its research.
- A recipient of the 2024 AWS IMAGINE Grant, the Institute plans to develop a new tool called GRAPE that combines generative and predictive AI to find new, more effective treatments for brain disorders such as
Read More
From Raw Records to Real-Time Insights: Climbing Pharma’s Real-World Data Maturity Curve
Real-world data (RWD) has become the pharmaceutical industry's most promising yet challenging frontier. While companies have long recognized its potential to complement clinical trials and deepen patient outcome insights, many still struggle to fully realize its value.
We’ve seen firsthand, from early discovery to market authorization to post-launch evidence generation, that extracting meaningful value from RWD requires more than just data acquisition. It demands a consistent, scalable, and
Read More
Nicoya Lifesciences Acquires Applied Photophysics to Accelerate Drug Discovery
What You Should Know:
- Nicoya Lifesciences, Inc., a leading provider of advanced biologics characterization tools for drug discovery and development, today announced its acquisition of Applied Photophysics, a UK-based provider of biophysical characterization instrumentation.
- Applied Photophysics, bringing a 50-year history of delivering established analytical methods and reliable instrumentation, will now operate as part of Nicoya.
Nicoya Expands Biopharmaceutical Analytics
Read More
Mission Bio Unveils Industry-First Single-Cell Genotype and Targeted Gene Expression Solution
What You Should Know:
- Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Single-Cell Genotype and Targeted Gene Expression assay, expanding the capabilities of its Tapestri Platform to become the only commercial solution that delivers simultaneous genotype and targeted gene expression profiling from over 10,000 single cells.
- The assay, which can be leveraged for Phase 2 or 3 trials to home in on patients most likely to
Read More
